Ccr 20th anniversary commentary: A chimeric antibody, c225, inhibits egfr activation and tumor growth

John Mendelsohn; Marie Prewett; Patricia Rockwell; Neil I. Goldstein

doi:10.1158/1078-0432.CCR-14-2491

Ccr 20th anniversary commentary: A chimeric antibody, c225, inhibits egfr activation and tumor growth

John Mendelsohn
, Marie Prewett
, Patricia Rockwell
, Neil I. Goldstein

Experimental Therapeutics

Research output: Contribution to journal › Review article › peer-review

31 Scopus citations

Abstract

Murine mAb 225 was effective against the EGFR tyrosine kinase and inhibited tumor growth in preclinical studies. A phase I trial showed safety, tumor localization, and satisfactory pharmacokinetics. Human:murine chimeric C225 retained biologic activity, which was essential for the conduct of subsequent combination therapy trials and eventual regulatory approval.

Original language	English (US)
Pages (from-to)	227-229
Number of pages	3
Journal	Clinical Cancer Research
Volume	21
Issue number	2
DOIs	https://doi.org/10.1158/1078-0432.CCR-14-2491
State	Published - Jan 15 2015

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-14-2491

Cite this

@article{923de83910ca4a158d616160283f1029,

title = "Ccr 20th anniversary commentary: A chimeric antibody, c225, inhibits egfr activation and tumor growth",

abstract = "Murine mAb 225 was effective against the EGFR tyrosine kinase and inhibited tumor growth in preclinical studies. A phase I trial showed safety, tumor localization, and satisfactory pharmacokinetics. Human:murine chimeric C225 retained biologic activity, which was essential for the conduct of subsequent combination therapy trials and eventual regulatory approval.",

author = "John Mendelsohn and Marie Prewett and Patricia Rockwell and Goldstein, \{Neil I.\}",

note = "Publisher Copyright: {\textcopyright} 2015 American Association for Cancer Research.",

year = "2015",

month = jan,

day = "15",

doi = "10.1158/1078-0432.CCR-14-2491",

language = "English (US)",

volume = "21",

pages = "227--229",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "2",

}

TY - JOUR

T1 - Ccr 20th anniversary commentary

T2 - A chimeric antibody, c225, inhibits egfr activation and tumor growth

AU - Mendelsohn, John

AU - Prewett, Marie

AU - Rockwell, Patricia

AU - Goldstein, Neil I.

PY - 2015/1/15

Y1 - 2015/1/15

N2 - Murine mAb 225 was effective against the EGFR tyrosine kinase and inhibited tumor growth in preclinical studies. A phase I trial showed safety, tumor localization, and satisfactory pharmacokinetics. Human:murine chimeric C225 retained biologic activity, which was essential for the conduct of subsequent combination therapy trials and eventual regulatory approval.

AB - Murine mAb 225 was effective against the EGFR tyrosine kinase and inhibited tumor growth in preclinical studies. A phase I trial showed safety, tumor localization, and satisfactory pharmacokinetics. Human:murine chimeric C225 retained biologic activity, which was essential for the conduct of subsequent combination therapy trials and eventual regulatory approval.

UR - https://www.scopus.com/pages/publications/84920982353

UR - https://www.scopus.com/pages/publications/84920982353#tab=citedBy

U2 - 10.1158/1078-0432.CCR-14-2491

DO - 10.1158/1078-0432.CCR-14-2491

M3 - Review article

C2 - 25593342

AN - SCOPUS:84920982353

SN - 1078-0432

VL - 21

SP - 227

EP - 229

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 2

ER -

Ccr 20th anniversary commentary: A chimeric antibody, c225, inhibits egfr activation and tumor growth

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this